 This study is an open-label study all people know the identity of the intervention in patients who are chronically infected with hepatitis C virus HCV genotype-1a GT1a or genotype-1b GT1b to assess the safety, tolerability and efficacy of the coadministration of TMC647055, TMC435 and low-dose ritonavir RTV, with and without ribavirin RBV and of TMC647055, TMC435, RTV administered together with GSK233680k without RBV for 12 weeks. Approximately 86 patients will be enrolled in this study. Patients enrolled in the study will be chronically infected with HCV of GT1a n10 or GT1b n20, either treatment-naive patients ie, patients never having received PegIFN Pegylated interferon alpha-2a at 180 mcg subcutaneous once a week, RBV, or any other approved or investigational treatment for chronic HCV infection or patients who are relapsers to prior treatment with PegIFN RBV ie, relapsers are patients with HCV ribonucleic acid RNA undetectable at the last on treatment measurement of a prior PegIFN based regimen of at least 24 weeks, but HCV RNA detectable within 1 year after the last medication intake. Patients in this first part of the study will be divided over 4 panels: Panel 1 will consist of 10 chronic HCV GT1a infected treatment-naive patientsprior relapsers who will receive 12 weeks of treatment with TMC435 TMC647055 low-dose ritonavir and ribavirin. Panel 2 will consist of 20 chronic HCV GT1b infected treatment-naive patients prior relapsers who will be randomly allocated to 2 arms in a 1:1 ratio. Arm 1 N10 will receive TMC435 TMC647055 low-dose ritonavir and ribavirin. Arm 2 N10 will receive TMC435 TMC647055 low-dose ritonavir. Panel 3 will consist of 16 chronic HCV GT1a or GT1b infected treatment-naïve patientsprior relapsers who will be allocated to 2 arms: 8 HCV GT1a patients in arm 1 and 8 HCV GT1b patients in arm 2. Patients in Arm 1 will receive 12 weeks of treatment with TMC435 TMC647055 low-dose RTV and RBV and patients in Arm 2 will receive 12 weeks of treatment with TMC435 TMC647055 low-dose RTV. Panel 4 will consist of 40 chronic HCV GT1a or GT1b infected treatment-naïve patientsprior relapsers who will be allocated to 2 arms: each arm will consist of 20 patients of which at most 8 patients will be infected with HCV GT1b. Patients will be randomized in 1:1 ratio between the 2 arms whereby randomization will be stratified by genotype. Patients in Arm 1 will receive 12 weeks of treatment with TMC435 TMC647055 low-dose RTV GSK2336805. Patients in Arm 2 will receive 12 weeks of treatment with TMC435 TMC647055 low-dose RTV GSK2336805. The planned duration of the investigational treatment is 12 weeks. Patients in Panels 1, 2, and 3 may receive follow-up treatment with 12 weeks or 36 weeks of PegIFNα RBV; follow-up treatment principles will not apply to Panel 4 as based on available proof of concept data for such combinations, the need for an additional 12 or 36-week PegIFNRBV follow-up therapy is expected to be very low when evaluating a 12-week regimen of 3 direct acting antiviral agents for treatment of HCV genotype 1 infections. Safety will be monitored throughout the study 